Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | IL-9 | 72.5 | 62 | |
RA2159 | TNF-a | 100 | ng/mL | 2 | IL-9 | 74.0 | 54 | ||||
N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | IL-9 | 56.0 | 57 | |
N2645 | TNF-a | 100 | ng/mL | 2 | IL-9 | 57.0 | 48 | ||||
RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | IL-9 | 65.0 | 47 | |
RA2708 | TNF-a | 100 | ng/mL | 2 | IL-9 | 67.0 | 38 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-9 | 46.0 | 69 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-9 | 49.5 | 64 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-9 | 43.5 | 58 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-9 | 46.0 | 54 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-9 | 38.0 | 55 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-9 | 50.0 | 44 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-9 | 59.5 | 64 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 2 | IL-9 | 53.0 | 41 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-9 | 45.5 | 36 | |
N2645 | IL-1 alpha | 100 | ng/mL | 2 | IL-9 | 49.0 | 57 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | IL-9 | 56.0 | 37 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 2 | IL-9 | 66.0 | 46 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | IL-9 | 39.5 | 56 | |
RA2159 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | IL-9 | 56.0 | 53 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | IL-9 | 40.0 | 61 | |
N2645 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | IL-9 | 42.5 | 58 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | IL-9 | 41.0 | 67 | |
RA2708 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 2 | IL-9 | 46.0 | 63 | |
RA2159 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 2 | IL-9 | 58.0 | 59 |